41082-79-5 Usage
Uses
Used in Pharmaceutical Industry:
4-METHOXY-6-INDOLE CARBOXYLIC ACID METHYL ESTER is used as a key intermediate in the development of drugs targeting the central nervous system. Its unique chemical structure allows for the creation of novel indole derivatives with potential biological activity, making it a valuable asset in the synthesis of new pharmaceutical compounds.
Used in Synthesis of Indole Derivatives:
In the field of organic chemistry, 4-METHOXY-6-INDOLE CARBOXYLIC ACID METHYL ESTER serves as a versatile building block for the synthesis of various indole derivatives. These derivatives can exhibit a range of biological activities, making them valuable for further research and development in the pharmaceutical and medical fields.
Used in Medical Research:
4-METHOXY-6-INDOLE CARBOXYLIC ACID METHYL ESTER is utilized in medical research for its potential applications in the development of new therapeutic agents. Its unique properties and chemical structure make it a promising candidate for the creation of innovative drugs and treatments for various medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 41082-79-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,1,0,8 and 2 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 41082-79:
(7*4)+(6*1)+(5*0)+(4*8)+(3*2)+(2*7)+(1*9)=95
95 % 10 = 5
So 41082-79-5 is a valid CAS Registry Number.
41082-79-5Relevant academic research and scientific papers
Kim, Musong,Vedejs, Edwin
, p. 6945 - 6948 (2004)
Cyclization of the Stobbe product 3 under the literature conditions (acetic anhydride/sodium acetate) affords both the indole 6 and the indolizine 8. The presence of base promotes the formation of indolizine products, and using acetic anhydride/triethylamine leads to indolizine products in good yield. Improved conditions for conversion to indoles 2, 5, and 6 are reported, and inconsistencies in some of the literature structure assignments and characterization data are noted.
Novel indolyl derivatives which are L-CPT1 inhibitors
-
Page/Page column 23, (2010/11/26)
The invention is concerned with novel heterobicyclic derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, A, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.
